

Why carry out this study?

- Optimum dose and interval for the control of disease activity with infliximab (IFX) treatment for rheumatoid arthritis have not been established.
- We investigated early-phase clinical indicators and serum factors associated with the efficacy of IFX treatment for rheumatoid arthritis after treatment for 1 year in daily practice.

What was learned from the study?

- Serum levels of interleukin (IL)-6 and IL-10 at baseline predict the efficacy after 1 year of treatment with IFX.
- Cases with high serum levels of IL-6 and IL-10 at baseline might require more intensive therapy to achieve higher rates of clinical remission at 1 year.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by by Eisai Co., Ltd. and by internal research grants from Keio University, Japan. Medical writing assistance for this study was provided by Dr. Guy Harris (DMC Corp.). For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).